Skip to main
VNDA

Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target

Vanda Pharmaceuticals (VNDA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Vanda Pharmaceuticals is expected to see a positive financial outlook in the coming years, driven by its strong commercial portfolio and a robust pipeline of therapeutics targeting various unmet medical needs. The company is currently focusing on expanding its presence in the US market and has a promising outlook for its Fanapt product, which generates the maximum revenue. Its other products also show potential for growth, including ASO molecules and VTR-297. Overall, Vanda Pharmaceuticals has strong opportunities for revenue growth and value creation, supported by its ongoing late-stage clinical trials and potential upcoming approvals.

Bears say

Vanda Pharmaceuticals is facing significant clinical and development risks as the success of their pipeline is heavily dependent on FDA approval. Financially, the company may need additional capital to fund further research and development which could negatively impact their cash balance and earnings. Furthermore, the company has faced product liability claims which could result in financial losses. These risks, combined with a headline revenue miss, make us reiterate our negative outlook on the company's stock.

Vanda Pharmaceuticals (VNDA) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vanda Pharmaceuticals (VNDA) Forecast

Analysts have given Vanda Pharmaceuticals (VNDA) a Buy based on their latest research and market trends.

According to 5 analysts, Vanda Pharmaceuticals (VNDA) has a Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vanda Pharmaceuticals (VNDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.